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report (Pintor et al, 1990). The editor ofthe Nev Englcand Jolunal
of Medicine at the time wrote an editorial to accompany that
retraction entitled 'An error corrected, a conclusion withdrawn,
and a lesson learned' (Relman, 1990). Unfortunately, this artifact-
prone assay remains in wide use. While many data exist in support
of a role for the IGF system in the pathogenesis of prostate cancer,
it is the autocrine-paracrine involvement of IGFs and IGFBPs that
is commonly implicated, as reviewed by Peehl et al (1996).
However, measurements of IGF-1 in two previous studies using
valid methodologies (Cohen et al, 1993; Ho and Baxter, 1997),
demonstrated normal serum levels, indicating that there is no rela-
tionship between circulating IGF-I levels and the prevalence of
prostate cancer. We would therefore like to encourage Mantzoros
et al (1997) to re-assay their patients' sera in an IGF-I assay,
which can be demonstrated to be free of IGFBP interference;
otherwise, their conclusions may not be valid.
P Cohen', D M Peehl2 acnd R Rosenfeld3x
'Children 's Hospital ofPhiladelphia, Unii'ersitr oftPennsylvaania,
Philadelphia, PA, USA; 2Department ofUrology; Stanford
Unii'ersitv Medical Center, Stanford, CA, USA; 3Department of
Pediatrics, Oregon Health Sciences University; Portland, ON, USA
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Insulin-like growth factor I in relation to prostate
cancer and benign prostatic hyperplasia - reply to the
letter from Cohen, Peehl and Rosenfeld
Sir,
We thank Dr Cohen and colleagues for their interest in our paper.
They may or may not be correct in their assertion that the labora-
tory procedure that we have used to measure insulin-like growth
factor I (IGF- 1) has reduced specificity, notwithstanding the manu-
facturers' claim of no interference. What they fail to realize,
however, is that their own study (Cohen et al, 1993) is actually
suggestive of a positive association between IGF-I and prostate
cancer. Indeed, had their study been as large as ours (51 cases and
52 controls), the difference between mean IGF-I levels of their
cases and controls would have been marginally significant
(P = 0.06). They have also made a mistake in their indication ofthe
'standard error' ofthe mean IGF-1 value, when, in reality, this must
have been the standard deviation - otherwise the standard deviation
of IGF-1 among their cases would have been much higher than
their mean value! There is a lesson here: lack of statistical signifi-
cance is frequently due to limited statistical power and should
never be the basis for a confident assertion of no association. The
other study that Cohen and colleagues refer to (Ho and Baxter,
1997) is even smaller than their own, with only seven controls.
Cohen and colleagues' claim also implies that a qualitatively
similar phenomenon would create an artificial positive association
between IGF-1 and benign prostatic hyperplasia (BPH), even
though in our study there was absolutely no relationship between
IGF- 1 and BPH after adjusting for confounding variables (Table 4
in Mantzoros et al, 1997). If they are still worried, however, they
could also look to the findings ofa new study recently published in
Science (Chan et al, 1998). Using a different assay, this study has
confirmed our findings almost to the decimal point.
CS Mantzoros"2, LB Signiorello' anid D Trichopoulos'
'Department ofEpidemiology anld Harvard Ceniterfoir cancer
Preventioni, Harvard School ofPublic Health, Bostoni, MA, USA;
2Division ofEndocrinology; Beth Israel Deaconess Medical
Ceniter, Harvard Medical School, Boston, MA, USA
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Suboptimal analysis using 'optimal' cutpoints
Sir,
Oncologyjournals continue to publish many papers evaluating the
prognostic importance of tumour markers in patients with various
cancers. There is no agreed statistical methodology for handling
such data, but some analyses are widely agreed to be misleading.
One in particular, the so-called 'optimal' cutpoint method, is
unsatisfactory for this purpose (Altman, 1991; Hilsenbeck et al,
1992; Hill, 1993; Altman et al, 1994, 1995). Regrettably, this
method, which is better referred to as the minimum P-value
method, continues to appear in papers published in the British
Journal ofCancer.
Briefly, the minimum P-value method is as follows:
(1) each distinct observed value ofthe marker is taken in turn as
a cutpoint and two groups ofpatients created with values
below or above this level (a variation is to use equi-spaced
values across the observed range);
(2) for each such grouping a log-rank test is performed and the
P-value determined;
(3) the cutpoint with the lowest P-value is called 'optimal',
Kaplan-Meier curves are constructed for groups created with
this cutpoint and the P-value reported;
(4) in most cases the resulting binary variable is included with
other variables in a Cox multiple regression analysis.
The dangers of this approach have been outlined (Altman et al,
1994) and include:
(a) because ofmultiple testing the false-positive rate is around
40% rather than the nominal 5%;
(b) the P-value is far too small (P = 0.002 corresponds to a
genuine P = 0.05);
(c) the value ofthe cutpoint has no clinical meaning;
(d) the analysis gives no information about the shape ofthe rela-
tion between the level of the tumour marker and prognosis.
In addition, when step (4) above is followed, the bias from the
univariate analysis is transferred to the multivariate setting
(Altman et al, 1994). It is not surprising, therefore, that such
analyses often show that the tumour marker is apparently more
important (i.e. has a smaller P-value) than other variables in
univariate analyses, and that they usually retain significance after
adjustment for standard risk factors. These problems arise from the
search for the 'best' result. The consequence is a cutpoint that may
be best in the narrow sense described, but which will not offer a
true indication ofthe importance ofthe tumour marker.
Looking quickly through a few recent issues of the journal I
found three such studies. Dettmar et al (1997) studied the prog-
nostic relevance of MIBl (Ki-67) and S-phase fraction (SPF) for
disease-free survival in node-negative breast cancer. The authors
followed steps (1) to (4) above and reported P-values of 0.0224
and 0.0028, respectively, for the two markers. When adjustment is
made for multiple testing (Altman et al, 1994), the corrected P-
values are unimpressive, being 0.29 and 0.06. The authors
performed Cox regression analysis using the two binary marker
indicators as well as established prognostic factors (none ofwhich
was significant in univariate analyses). They report that SPF was
the only significant variable in the Cox analysis and that it was
(therefore) the strongest prognostic factor.
Buer et al (1997) studied the relation of serum levels of S100
and survival in metastatic malignant melanoma. These authors
also followed steps (1) to (4). The P-value for the optimal cutpoint
was reported as P < 0.001, which converts to P < 0.025 after
adjustment. S100 was not found to retain its prognostic value in a
Cox analysis. Gustafson et al (1997) probably also followed the
four steps above, although they do not state explicitly that they
minimized the P-value. These authors examined multiple
cutpoints in the study of SPF in soft-tissue sarcoma. SPF retained
its significance in the multivariate model, ahead ofother variables,
including grade of malignancy.
It is worrying that many authors, not only in this journal,
continue to use this dubious methodology, especially after its defi-
ciencies have been highlighted several times. Calling the method
'optimal' attaches an unwarranted and inappropriate cachet to a
highly suboptimal strategy. Dozens of papers have used this
dubious method, including, I am sure, many that have not declared
it (as many papers do not explain their choice ofcutpoint; Altman
et al, 1995). No authors have cited a statistical text or paper to
support the method, of which I believe there is none, although
some authors have investigated ways to improve the procedure
(Faraggi and Simon, 1996; Hilsenbeck and Clark, 1996).
While misleading results from individual studies are undesir-
able, they may also distort the results of a subsequent meta-
analysis. Ferrandina et al (1997) recently described a
meta-analysis of 11 studies that examined the relation between
cathepsin D and disease-free survival in breast cancer. They
reported that authors had used cutpoints in the range 24-78 pmol
mg-'. They noted that interstudy heterogeneity in the relative risk
was 'remarkably high'. Some of the heterogeneity is likely to be
due to the use of the minimum P-value method in some studies.
The authors of the meta-analysis commented on this possibility,
but did not compare results according to the method of deriving
the cutpoint. Indeed, one of the studies included by Ferrandina et
al found a significant cutpoint using exploratory multiple cutpoint
analyses, but the authors concluded from further analyses that this
finding was unsound (Ravdin et al, 1994). It would be helpful to
have results of such meta-analyses related to the method of selec-
tion of the cutpoint or, better still, based on the raw data without
the use of cutpoints.
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